Cancer Incidence in Persons Living With HIV

<span class="paragraphSection">T<span style="text-transform:lowercase;font-variant:small-caps;">o the</span> E<span style="text-transform:lowercase;font-variant:small-caps;">ditor</span>—We read with interest the report by Borges et al [<a href="#CIT0001" class="reflinks">1</a>] assessing the cancer incidence in person living with human immunodeficiency virus (HIV) who start antiretroviral treatment (ART) immediately or who defer until CD4 counts drop to <350 cells/µL. The Strategic Timing of Antiretroviral Treatment (START) study is a multicenter, randomized trial including 4685 naive people living with HIV from 35 countries worldwide [<a href="#CIT0002" class="reflinks">2</a>].</span>

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jS8s5Q
via IFTTT